A cost-effectiveness analysis suggests that dostarlimab plus carboplatin-paclitaxel may be a valuable first-line treatment option for patients with primary advanced or recurrent endometrial cancer.
A cost-effectiveness analysis suggests that dostarlimab plus carboplatin-paclitaxel may be a valuable first-line treatment option for patients with primary advanced or recurrent endometrial cancer.
A cost-effectiveness analysis...
